Selecta Biosciences, Inc. (SELB)
Stock Price:
$2.57 USD
-0.04 (-1.53%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
275.36M |
| Revenue (ttm) |
6.65M |
| Net Income (ttm) |
-70.58M |
| Shares Out |
107.14M |
| EPS (ttm) |
-0.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.57 |
| Previous Close |
$2.61 |
| Change ($) |
-0.04 |
| Change (%) |
-1.53% |
| Day's Open |
2.62 |
| Day's Range |
2.55 - 2.63 |
| Day's Volume |
443,538 |
| 52-Week Range |
1.28 - 4.83 |
More Stats
| Market Cap |
275.36M |
| Enterprise Value |
241.95M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
107.14M |
| Float |
81.85M |
| EPS (basic) |
-1 |
| EPS (diluted) |
-0.97 |
| FCF / Share |
-0.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.30M |
| Short Ratio |
6.72 |
| Short % of Float |
10.25% |
| Beta |
1.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
41.38 |
| PB Ratio |
31.26 |
| Revenue |
6.65M |
| Operating Income |
-66.21M |
| Net Income |
-70.58M |
| Free Cash Flow |
-47.79M |
| Net Cash |
33.41M |
| Net Cash / Share |
0.31 |
| Gross Margin |
-307.66% |
| Operating Margin |
-995.00% |
| Profit Margin |
n/a |
| FCF Margin |
-718.21% |
| ROA |
-60.94% |
| ROE |
-2,077.15% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
6 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.17*
(217.90% upside)
Low
4.00
Current: $2.57
High
13.00
Target: 8.17
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -59.13 | -65.93 | -63.99 | -42.75 | -31.32 | -18.44 |
| Net Income | -55.35 | -65.34 | -65.32 | -36.21 | -25.17 | -12.88 |
| Shares Outstanding | 45.55 | 22.39 | 20.43 | 10.49 | 2.15 | 2.09 |
| Earnings Per Share | -1.22 | -2.92 | -3.20 | -3.89 | -15.13 | -7.84 |
| Operating Cash Flow | -51.44 | -59.16 | -52.03 | -19.76 | -22.46 | -12.69 |
| Capital Expenditures | 0.08 | -0.79 | -0.73 | -0.58 | -1.16 | -0.23 |
| Free Cash Flow | -51.36 | -59.95 | -52.76 | -20.34 | -23.63 | -12.91 |
| Cash & Equivalents | 90.17 | 37.40 | 96.64 | 84.54 | 36.91 | 18.94 |
| Total Debt | 19.28 | 21.39 | 21.04 | 12.04 | 11.86 | 7.40 |
| Net Cash / Debt | 70.90 | 16.02 | 75.60 | 72.49 | 25.06 | 11.54 |
| Assets | 99.57 | 44.48 | 101 | 89.30 | 42.82 | 22.23 |
| Liabilities | 91.17 | 49.90 | 49.29 | 34.34 | 21.84 | 15.95 |
| Book Value | 8.40 | -5.42 | 51.81 | 54.96 | -116 | -87.76 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Selecta Biosciences, Inc. |
| Country |
United States |
| Employees |
39 |
| CEO |
Carsten Brunn |
Stock Information
| Ticker Symbol |
SELB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SELB |
| IPO Date |
June 22, 2016 |
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. The company has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., Asklepios BioPharmaceutical, Inc., and Sarepta Therapeutics, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.